Elevated CETP activity improves plasma cholesterol efflux capacity from human macrophages in women

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 10, 2012, Pages 2341-2349

  Villard, Elise F ^a,b,c   El Khoury, Petra ^a,b,c   Duchene, Emilie ^a,c   Bonnefont Rousselot, Dominique ^a,c,d   Clement, Karine ^a,b,c,e   Bruckert, Eric ^a,b,c   Bittar, Randa ^a,b,c   Le Goff, Wilfried ^a,b,c   Guerin, Maryse ^a,b,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Institute of Cardiometabolism and Nutrition   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

Author keywords

ATP binding cassette transporter; cellular cholesterol efflux; cholesteryl ester transfer protein; lipoproteins; macrophages

Indexed keywords

ABC TRANSPORTER A1; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACUTE MONOCYTIC LEUKEMIA; ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MACROPHAGE; MAJOR CLINICAL STUDY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; FEMALE; HUMANS; LEUKEMIA, MONOCYTIC, ACUTE; LIPOPROTEINS, HDL; MACROPHAGES; MIDDLE AGED; MULTIVARIATE ANALYSIS;

EID: 84866619765     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.252841     Document Type: Article

References (58)

1. Gordon DJ, Rifkind BM. High-density lipoprotein-the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
2. Camont L, Chapman MJ, Kontush A. Biological activities of HDL sub-populations and their relevance to cardiovascular disease. Trends Mol Med. 2011;17:594-603.
3. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol effux capacity, high-density lipo-protein function, and atherosclerosis. N Engl J Med. 2011;364:127-135.
4. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol effux: implications for the treatment of atherosclerosis. Cell Metab. 2008;7:365-375.
5. Guerin M. Reverse cholesterol transport in familial hypercholesterol- emia. Curr Opin Lipidol. 2012;23:16.
6. Adorni MP, Zimetti F, Billheimer JT, Wang N, Rader DJ, Phillips MC, Rothblat GH. The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res. 2007;48:2453-2462.
7. Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, Rothblat GH, Tall AR, Rader DJ. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007;117:2216-2224.
8. Larrede S, Quinn CM, Jessup W, Frisdal E, Olivier M, Hsieh V, Kim MJ, Van Eck M, Couvert P, Carrie A, Giral P, Chapman MJ, Guerin M, Le Goff W. Stimulation of cholesterol effux by LXR agonists in cholesterol-loaded human macrophages is ABCA1-dependent but ABCG1-independent. Arterioscler Thromb Vasc Biol. 2009;29:1930-1936.
9. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96:1221-1232.
10. Guérin M, Dolphin PJ, Chapman MJ. A new in vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass transfer between HDL and apoB-containing lipoprotein subspecies. Identifcation of preferential cholesteryl ester acceptors in human plasma. Arterioscler Thromb. 1994;14:199-206.
11. Lassel TS, Guérin M, Auboiron S, Chapman MJ, Guy-Grand B. Preferential cholesteryl ester acceptors among triglyceride-rich lipopro-teins during alimentary lipemia in normolipidemic subjects. Arterioscler Thromb Vasc Biol. 1998;18:65-74.
12. Schwartz CC, VandenBroek JM, Cooper PS. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res. 2004;45:1594-1607.
13. Le Goff W, Guerin M, Chapman MJ. Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. Pharmacol Ther. 2004;101:17-38.
14. Kunitake ST, Mendel CM, Hennessy LK. Interconversion between apo-lipoprotein A-I-containing lipoproteins of pre-beta and alpha electropho-retic mobilities. J Lipid Res. 1992;33:1807-1816.
15. Lagrost L, Athias A, Herbeth B, Guyard-Dangremont V, Artur Y, Paille F, Gambert P, Lallemant C. Opposite effects of cholesteryl ester transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins. Physiological relevance in alcoholic patients. J Biol Chem. 1996;271:19058-19065.
16. Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, Whitlock ME, Marcel YL, Milne RW, Koizumi J, Mabuchi H. Molecular basis of lipid transfer protein defciency in a family with increased high-density lipo-proteins. Nature. 1989;342:448-451.
17. Ikewaki K, Rader DJ, Sakamoto T, Nishiwaki M, Wakimoto N, Schaefer JR, Ishikawa T, Fairwell T, Zech LA, Nakamura H, Nagano M, Brewer HB Jr. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein defciency. J Clin Invest. 1993;92:1650-1658.
18. Lagrost L, Gandjini H, Athias A, Guyard-Dangremont V, Lallemant C, Gambert P. Infuence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profles in normolipidemic subjects. Arterioscler Thromb. 1993;13:815-825.
19. Rye KA, Barter PJ. Formation and metabolism of prebeta-migrat-ing, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol. 2004;24:421-428.
20. Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fbrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J. 2010;31:149-164.
21. Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, Fisher T, Sparrow CP, Taggart AK, Tall AR. Cholesterol effux potential and antiinfamma-tory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol. 2010;30:1430-1438.
22. Yvan-Charvet L, Matsuura F, Wang N, Bamberger MJ, Nguyen T, Rinninger F, Jiang XC, Shear CL, Tall AR. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol effux to HDL. Arterioscler Thromb Vasc Biol. 2007;27:1132-1138.
23. Bellanger N, Julia Z, Villard EF, El Khoury P, Duchene E, Chapman MJ, Fournier N, Le Goff W, Guerin M. Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy. Atherosclerosis. 2012;221:160-168.
24. Catalano G, Duchene E, Julia Z, Le Goff W, Bruckert E, Chapman MJ, Guerin M. Cellular SR-BI and ABCA1-mediated cholesterol effux are gender-specifc in healthy subjects. J Lipid Res. 2008;49:635-643.
25. Catalano G, Julia Z, Frisdal E, Vedie B, Fournier N, Le Goff W, Chapman MJ, Guerin M. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arterioscler Thromb Vasc Biol. 2009;29:268-275.
26. Gelissen IC, Harris M, Rye KA, Quinn C, Brown AJ, Kockx M, Cartland S, Packianathan M, Kritharides L, Jessup W. ABCA1 and ABCG1 syner-gize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol. 2006;26:534-540.
27. Sankaranarayanan S, Oram JF, Asztalos BF, Vaughan AM, Lund-Katz S, Adorni MP, Phillips MC, Rothblat GH. Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol effux. J Lipid Res. 2009;50:275-284.
28. Tréguier M, Moreau M, Sposito A, Chapman MJ, Huby T. LDL particle subspecies are distinct in their capacity to mediate free cholesterol effux via the SR-BI/Cla-1 receptor. Biochim Biophys Acta. 2007;1771:129-138.
29. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol effux to high-density lipoproteins. Proc Natl Acad Sci USA. 2004;101:9774-9779.
30. Favari E, Calabresi L, Adorni MP, Jessup W, Simonelli S, Franceschini G, Bernini F. Small discoidal pre-beta1 HDL particles are effcient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry. 2009;48:11067-11074.
31. Davidson WS, Rodrigueza WV, Lund-Katz S, Johnson WJ, Rothblat GH, Phillips MC. Effects of acceptor particle size on the effux of cellular free cholesterol. J Biol Chem. 1995;270:17106-17113.
32. Davit-Spraul A, Atger V, Pourci ML, Hadchouel M, Legrand A, Moatti N. Cholesterol effux from Fu5AH cells to the serum of patients with Alagille syndrome. Importance of the hdl-phospholipids/free cholesterol ratio and of the hdl size distribution. J Lipid Res. 1999;40:328-335.
33. Asztalos BF, de la Llera-Moya M, Dallal GE, Horvath KV, Schaefer EJ, Rothblat GH. Differential effects of HDL subpopulations on cellular ABCA1-and SR-BI-mediated cholesterol effux. J Lipid Res. 2005;46:2246-2253.
34. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote effux via ABCA1 determines the capacity of serum specimens with similar high-density lipopro-tein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010;30:796-801.
35. Hoang A, Drew BG, Low H, Remaley AT, Nestel P, Kingwell BA, Sviridov D. Mechanism of cholesterol effux in humans after infusion of reconstituted high-density lipoprotein. Eur Heart J. 2012;33:657-665.
36. Huang Y, von Eckardstein A, Assmann G. Cell-derived unesterifed cholesterol cycles between different HDLs and LDL for its effective esteri-fcation in plasma. Arterioscler Thromb. 1993;13:445-458.
37. Greene DJ, Skeggs JW, Morton RE. Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI). J Biol Chem. 2001;276:4804-4811.
38. Phillips MC, Johnson WJ, Rothblat GH. Mechanisms and consequences of cellular cholesterol exchange and transfer. Biochim Biophys Acta. 1987;906:223-276.
39. Wang Y, Snel M, Jonker JT, Hammer S, Lamb HJ, de Roos A, Meinders AE, Pijl H, Romijn JA, Smit JW, Jazet IM, Rensen PC. Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases plasma CETP and increases apolipoprotein AI levels without improving the cholesterol effux properties of HDL. Diabetes Care. 2011;34:2576-2580.
40. Aron-Wisnewsky J, Julia Z, Poitou C, Bouillot JL, Basdevant A, Chapman MJ, Clement K, Guerin M. Effect of bariatric surgery-induced weight loss on SR-BI-, ABCG1-, and ABCA1-mediated cellular cholesterol effux in obese women. J Clin Endocrinol Metab. 2011;96:1151-1159.
41. Niesor EJ. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Curr Opin Lipidol. 2011;22:288-295.
42. Schaefer EJ, Asztalos BF. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction. Am J Cardiol. 2007;100(11 A):n25-n31.
43. Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res. 2006;47:537-552.
44. Sirtori CR. Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention. Expert Opin Investig Drugs. 2011;20: 1543-1554.
45. Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains effcient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010;51:3443-3454.
46. Hooper AJ, Burnett Jr. Dalcetrapib, a cholesteryl ester transfer protein modulator. Expert Opin Investig Drugs. 2012;9:1427-1432.
47. Bersot TP, Vega GL, Grundy SM, Palaoglu KE, Atagündüz P, Ozbayrakçi S, Gökdemir O, Mahley RW. Elevated hepatic lipase activity and low levels of high density lipoprotein in a normotriglyceridemic, nonobese Turkish population. J Lipid Res. 1999;40:432-438.
48. Zhang X, Moor AN, Merkler KA, Liu Q, McLean MP. Regulation of alternative splicing of liver scavenger receptor class B gene by estrogen and the involved regulatory splicing factors. Endocrinology. 2007;148:5295-5304.
49. Kappelle PJ, Perton F, Hillege HL, Dallinga-Thie GM, Dullaart RP. High plasma cholesteryl ester transfer but not CETP mass predicts incident cardiovascular disease: a nested case-control study. Atherosclerosis. 2011;217:249-252.
50. Khera AV, Wolfe ML, Cannon CP, Qin J, Rader DJ. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-throm-bolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study). Am J Cardiol. 2010;106:451-456.
51. Ritsch A, Scharnagl H, Eller P, Tancevski I, Duwensee K, Demetz E, Sandhofer A, Boehm BO, Winkelmann BR, Patsch JR, März W. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation. 2010;121:366-374.
52. Brousseau ME, Eberhart GP, Dupuis J, Asztalos BF, Goldkamp AL, Schaefer EJ, Freeman MW. Cellular cholesterol effux in heterozygotes for tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size. J Lipid Res. 2000;41:1125-1135.
53. Mukhamedova N, Escher G, D'Souza W, Tchoua U, Grant A, Krozowski Z, Bukrinsky M, Sviridov D. Enhancing apolipoprotein A-I-dependent cholesterol effux elevates cholesterol export from macrophages in vivo. J Lipid Res. 2008;49:2312-2322.
54. Wang MD, Franklin V, Marcel YL. In vivo reverse cholesterol transport from macrophages lacking ABCA1 expression is impaired. Arterioscler Thromb Vasc Biol. 2007;27:1837-1842.
55. Aiello RJ, Brees D, Bourassa PA, Royer L, Lindsey S, Coskran T, Haghpassand M, Francone OL. Increased atherosclerosis in hyperlip-idemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol. 2002;22:630-637.
56. Van Eck M, Singaraja RR, Ye D, Hildebrand RB, James ER, Hayden MR, Van Berkel TJ. Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol. 2006;26:929-934.
57. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300.
58. Favari E, Gomaraschi M, Zanotti I, Bernini F, Lee-Rueckert M, Kovanen PT, Sirtori CR, Franceschini G, Calabresi L. A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding Cassette A1-mediated cell cholesterol effux. J Biol Chem. 2007;282: 5125-5132.